The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001379303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/09/2026
Date registered
Help: Date registered
17/11/2026
Date last updated
Help: Date last updated
17/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of BMB-101 on seizure frequency and safety in people with absence seizures
Scientific title
An Open Label Phase 2b Study to Evaluate the Efficacy and Safety of Ascending Doses of BMB-101 to a Maximum Tolerated Dose for the Treatment of Absence Seizures
Additional trial identifiers [1] 318079 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Absence seizures 343101 0
Condition category
Condition code
Neurological 339190 339190 0 0
Epilepsy
Neurological 340075 340075 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Procedures surrounding intervention: after administration up to a 250 mL glass of water or other fluids (e.g., fruit juice) may be consumed after taking the study drug.

Intervention is administered by study team and participant.

Intervention is administered in-patient hospital and at home.

Intervention drug will be increased depending on tolerability at 0.33 mg/kg, increased weekly up to 2.0 mg/kg. Participants who do not tolerate the initial dose of 0.33 mg/kg may be allowed, at the discretion of the investigator and the sponsor, to halve the dose to 0.165 mg/kg and then titrate up to 0.33 mg/kg the following week.

Screening window is an out-patient visit where participant performs an ECG, physical exam, vital signs, height and weight, collects blood and urine samples for safety labs, a drug screen, and a pregnancy test for women of childbearing potential, completes the C-SSRS (suicidality) and CGI-S (illness severity) questionnaires, performs a 24-hour ambulatory EEG with photic stimulation and hyperventilation.

Study visits:
- Screening Period: 14 days
- Treatment Period: 7 weeks inclusive of a titration period of up to 5 weeks and maintenance period for an additional 2 weeks
- Open-label Treatment Period: Until the drug receives regulatory approval or the research program is terminated
- Follow-up Period: up to 5 weeks for those who elect to discontinue after the 7-week treatment period

Adherence will be monitored by recording each dose in the Dosing Diary.
Intervention code [1] 335291 0
Treatment: Drugs
Description of the comparator or control
No control group - study is open label
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346818 0
Absence seizure frequency, as assessed by video EEG.
Timepoint [1] 346818 0
The change in seizure frequency between Visit 2 (Baseline, Week -1) in-patient EEG assessment and Visit 9 (end of Main Phase, Week 7) in-patient EEG assessment.
Secondary outcome [1] 467682 0
Absence seizure frequency, as assessed by seizure diary.
Timepoint [1] 467682 0
The change in seizure frequency between Visit 2 (Baseline, Week -1) in-patient EEG Seizure Diary and Visit 9 (end of Main Phase, Week 7) in-patient EEG Seizure Diary.
Secondary outcome [2] 467683 0
Overall quality of life in participants with absence seizures.
Timepoint [2] 467683 0
Change in QOLIE scores performed at Screening (Week -2), Visit 3 (Week 0), Visit 8 (Week 5) and Visit 9 (Week 7).
Secondary outcome [3] 469557 0
Overall quality of life in participants with absence seizures.
Timepoint [3] 469557 0
Change in CGI-S scores performed at Screening (Week -2), Visit 3 (Week 0), Visit 8 (Week 5) and Visit 9 (Week 7).
Secondary outcome [4] 469558 0
Overall quality of life in participants with absence seizures.
Timepoint [4] 469558 0
Change in CGI-I scores performed at Screening (Week -2), Visit 3 (Week 0), Visit 8 (Week 5) and Visit 9 (Week 7).
Secondary outcome [5] 470361 0
Adverse Events
Timepoint [5] 470361 0
Adverse events reported from time of informed consent (Week -2) to end of Visit 9 (end of Main Phase, Week 7)
Secondary outcome [6] 470362 0
Safety Laboratory Assessments
Timepoint [6] 470362 0
Clinical Safety Laboratory Tests taken at Screening (Week -2), Visit 3 (Week 0), Visit 8 (Week 5) and Visit 9 (Week 7), and unscheduled visits (if they occur).
Secondary outcome [7] 470363 0
Vital Signs
Timepoint [7] 470363 0
Vital sign assessment conducted at Screening (Week -2), Visit 2 Day-5 (Week -1), Visit 2 Day -1 (Week -1), Visit 3 (Week 0), Visit 8 (Week 5), Visit 9 Day 49 (Week 7) and Visit 9 Day 53 (end of Main Phase, Week 7), and unscheduled visits (if they occur).
Secondary outcome [8] 470364 0
Physical Examinations
Timepoint [8] 470364 0
Physical examinations conducted at Screening (Week -2), Visit 2 (Week -1), Visit 3 (Week 0), Visit 8 (Week 5), Visit 9 (end of Main Phase, Week 7).
Secondary outcome [9] 470365 0
Columbia-Suicide Severity Rating Scale (C-SSRS) scores
Timepoint [9] 470365 0
Change in C-SSRS scores between Screening (Week -2), Visit 3 (Week 0), Visit 8 (Week 5) and Visit 9 (Week 7).

Eligibility
Key inclusion criteria
Confirmed diagnosis of typical absence seizures, defined as GSWD’s of approximately 3Hz on EEG

Minimum of ten (10) 3-seconds or greater duration GSWD in a 24-hour ambulatory EEG at Visit 1/Screening.

Minimum of ten (10) 3-seconds or greater duration GSWD each day of continuous video EEG recordings at Visit 2/Baseline (10 per day in Baseline).

At least one anti-seizure medication (ASM) at a recommended dose and duration and must be on a stable dose of their current ASMs or therapies for at least 4 weeks prior to screening and remain stable throughout the study. A maximum of 4 concomitant ASMs are allowed for enrollment.

Aged 18-65 years inclusive, at the time of consent
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Current or history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, pulmonary arterial hypertension, myocardial infarction or stroke, or clinically significant structural cardiac abnormality

Moderate or severe hepatic impairment. Asymptomatic participants with mild hepatic impairment (elevated liver enzymes <3x upper limit of normal [ULN] and/or elevated total bilirubin 470 msec (females)

A current C-SSRS score of 4 or 5 at Screening or history of suicide attempt at any time during the past year

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
This study is exploratory in nature, and all analyses will be descriptive. The statistical analysis plan (SAP) will be finalized prior to database lock.

As this is a phase 2b, open-label, single-arm study, no formal statistical hypotheses will be tested. Descriptive summaries of efficacy endpoints, including point estimates and measures of variability, will be used to evaluate trends in dose-response and to inform the design of subsequent controlled studies.

The study attempts to enroll 20 participants with 3-sec GSWD absence seizures to attain 12 who complete the treatment period (Visit 9).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 30196 0
The Alfred - Melbourne
Recruitment hospital [2] 30197 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 46591 0
3004 - Melbourne
Recruitment postcode(s) [2] 46592 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 322639 0
Commercial sector/Industry
Name [1] 322639 0
Bright Minds Bioscience Pty Ltd
Country [1] 322639 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Bright Minds Bioscience Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325561 0
None
Name [1] 325561 0
Address [1] 325561 0
Country [1] 325561 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321097 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 321097 0
Ethics committee country [1] 321097 0
Australia
Date submitted for ethics approval [1] 321097 0
22/06/2026
Approval date [1] 321097 0
27/07/2026
Ethics approval number [1] 321097 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152654 0
Prof Terence O'Brien
Address 152654 0
Alfred Health, The Alfred Centre, Level 6, 99 Commercial Rd, Melbourne VIC 3004
Country 152654 0
Australia
Phone 152654 0
+61 3 9903 0855
Fax 152654 0
Email 152654 0
Contact person for public queries
Name 152655 0
Rachelle Kirk-Burnnand
Address 152655 0
Bright Minds Bioscience Pty Ltd, Suite 1, Level 3, 62 Lygon Street Carlton South VIC 3053
Country 152655 0
Australia
Phone 152655 0
+61 439 615 368
Fax 152655 0
Email 152655 0
Contact person for scientific queries
Name 152656 0
Rachelle Kirk-Burnnand
Address 152656 0
Bright Minds Bioscience Pty Ltd, Suite 1, Level 3, 62 Lygon Street Carlton South VIC 3053
Country 152656 0
Australia
Phone 152656 0
+61 439 615 368
Fax 152656 0
Email 152656 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: De-identified participant data will be aggregated and analysed as populations. Raw line-by-line data collected from each participant will not be available publicly. Final electronic Case Report Forms may be made available privately to principal investigators at the conclusion of the study.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.